Neuronetics is trading 6.1% down at $2.27 on October 30, 2026; available information does not establish a specific reason for the decline.
- No clear company-specific announcement or other catalyst explaining the drop surfaced in available coverage.
- The company had previously scheduled its third-quarter results for November 4.
- Healthcare stocks were higher Friday afternoon: the NYSE Healthcare Index was up 1.1% and XLV was up 0.8%.